You are here: Industry Insights > Sanofi

News List

Libtayo® with chemotherapy trial stopped early due to success europeanpharmaceuticalreview
August 10, 2021
Phase III trial of Libtayo® (cemiplimab) combined with chemotherapy stops early due to significant improvement in overall survival in lung cancer patients.
Sanofi and Regeneron’s Libtayo trial stops early due to survival improvement pharmatimes
August 09, 2021
A Phase III trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) in combination with platinum-doublet chemotherapy has been stopped early after meeting its overall survival (OS) primary endpoint in patients with advanced non-small cell ...
US FDA approves Nexviazyme for late-onset Pompe disease expresspharma
August 09, 2021
The approval is based on the positive phase-III data demonstrating improvements in key disease burden measures and establishing its safety profile.
Sanofi to Acquire Translate Bio for $3.2B contractpharma
August 05, 2021
Upgrades drug formulation capabilities and accelerates development of licensed programs in vaccines and potential to explore other therapeutic areas.
Sanofi to acquire mRNA therapies developer Translate Bio for $3.2bn pharmaceutical-technology
August 04, 2021
Sanofi has signed a definitive agreement to acquire 100% outstanding shares of a messenger RNA (mRNA) therapies company, Translate Bio, for a total equity value of nearly $3.2bn, or $38 per share in cash.
Sanofi offers to buy U.S. mRNA partner Translate Bio firstwordpharma
August 03, 2021
Two sources familiar with the situation said Monday that Sanofi has offered to buy Translate Bio as the French drugmaker bets on next-generation mRNA technology following setbacks in the COVID-19 vaccine race, as reported in This is Money.
Sanofi reports 12.4% sales growth in Q2 2021 pharmaceutical-technology
August 02, 2021
Sanofi has reported net sales of $10.32bn (€8.7bn) in the second quarter (Q2) of 2021, a surge of 6.5% on a reported basis from $9.73bn (€8.2bn) in the same quarter last year.
Sanofi, Regeneron’s Dupixent wins positive results in chronic spontaneous urticaria pharmatimes
July 30, 2021
Sanofi and Regeneron’s interleukin-4 (IL-4) and interleukin-13 (IL-13) inhibitor Dupixent has demonstrated positive pivotal results in chronic spontaneous urticaria (CSU) – a chronic inflammatory skin disease.
EU begins real-time review of Sanofi-GSK COVID-19 vaccine expresspharma
July 22, 2021
The decision to start the "rolling review" of the vaccine, Vidprevtyn, was based on preliminary results from lab studies and early-stage clinical trials in adults, the European Medicines Agency (EMA) said.
FDA Approves Fexinidazole as the First All-Oral Treatment for Sleeping Sickness drugs
July 20, 2021
The US Food and Drug Administration (FDA) has approved fexinidazole as the first all-oral treatment for both stages of the Trypanosoma brucei gambiense form of sleeping sickness in patients 6 years of age and older and weighing at least 20 kg.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 43 44 Next page